Gilead Sciences (GILD) on Monday said it would acquire privately held Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases. The agreement includes $1.675 ...
When a virus enters the lungs, the immune system has to react fast. The lung maintains its own community of immune cells ...
This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...
MARCH 18, 2026, NEW YORK - The immune system's killer T cells do a commendable job of detecting and destroying cancer cells.
Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...
A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...
Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and ...
Morning Overview on MSN
Study shows immune cells can be engineered inside the body to fight cancer
Scientists have built functional cancer-fighting immune cells directly inside living animals, skipping the expensive and time ...
Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.
There are many different ways that doctors treat cancer, from chemotherapy to surgery. Another part of cancer treatment that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results